Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06676579 · ClinicalTrials.gov registry record · Phase 2
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
A Phase 2 study of IgA Nephropathy (IgAN), sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT06676579: Recruiting Phase 2 study of IgA Nephropathy (IgAN), sponsored by Mayo Clinic.
NCT06676579 is a Phase 2 study of IgA Nephropathy (IgAN) that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06676579, a Phase 2 study of IgA Nephropathy (IgAN), is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Primary Outcome
A response is based on the average of proteinuria quantified twice over a 2-weeks period at 12 months.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Prednisolone
- DRUG Avacopan
- DRUG Methylprednisolone (drug)
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-03-02 |
| Phase | Phase 2 |
What NCT06676579 shows while recruiting
NCT06676579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with IgA Nephropathy (IgAN) appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT06676579 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06676579 about?
NCT06676579 is a clinical study titled "Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)". The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
What is the current status of trial NCT06676579?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2025-06-09. Estimated completion is 2029-03-02.
What conditions does trial NCT06676579 study?
This clinical trial studies the following conditions: IgA Nephropathy (IgAN).
What interventions are being tested in trial NCT06676579?
The interventions under investigation include: Prednisone (DRUG), Prednisolone (DRUG), Avacopan (DRUG), Methylprednisolone (drug) (DRUG).
Who is sponsoring clinical trial NCT06676579?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06676579 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgA Nephropathy (IgAN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06676579's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI